Retrospective Cohort Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 26, 2024; 12(6): 1063-1075
Published online Feb 26, 2024. doi: 10.12998/wjcc.v12.i6.1063
Correlative factors of poor prognosis and abnormal cellular immune function in patients with Alzheimer’s disease
Hua Bai, Hong-Mei Zeng, Qi-Fang Zhang, Yue-Zhi Hu, Fei-Fei Deng
Hua Bai, Department of Neurology, The Third Affiliated Hospital of Guizhou Medical University in China, Duyun 558099, Guizhou Province, China
Hong-Mei Zeng, Yue-Zhi Hu, Fei-Fei Deng, Department of Neurology, Guizhou Medical University, Duyun 558099, Guizhou Province, China
Qi-Fang Zhang, Key Laboratory of Medical Molecular Biology, Guizhou Medical University, Guiyang 550004, Guizhou Province, China
Author contributions: Bai H contributed to study design, fundraising, and manuscript preparation; Bai H, Zeng HM, Hu YZ, and Deng FF contributed to investigation and data collection; Zeng HM, Zhang QF, and Bai H contributed to results analysis and discussion; all authors approved the final version of this manuscript.
Supported by the National Natural Science Foundation of China, No. 3206080019 and No. 32060182; Science and Technology Support Plan of Guizhou Province in China, No. [2020]4Y129; and Qiannan Prefecture Science and Technology Plan Project, No. [2022]01.
Institutional review board statement: The study was reviewed and approved by the Third Affiliated Hospital of Guizhou Medical University (Approval No. 20162160).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at baih2020@gmc.edu.cn.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hua Bai, MD, PhD, Full Professor, Department of Neurology, The Third Affiliated Hospital of Guizhou Medical University in China, No. 172 JianJiangbei Road, Duyun 558099, Guizhou Province, China. baih2020@gmc.edu.cn
Received: October 26, 2023
Peer-review started: October 26, 2023
First decision: December 15, 2023
Revised: December 21, 2023
Accepted: January 29, 2024
Article in press: January 29, 2024
Published online: February 26, 2024
Processing time: 117 Days and 0.5 Hours
Core Tip

Core Tip: Abnormal cellular immune function, extrapyramidal symptoms, abnormal electroencephalogram, increased neutrophils and lymphocyte ratio, abnormal magnetic spectroscopy, and complicated pneumonia were related to the poor prognosis of Alzheimer’s disease (AD) patients. The decrease in the proportion of T lymphocytes in the blood after abnormal cellular immune function was an independent risk factor for predicting the poor prognosis of AD. The number of days of donepezil treatment to improve cognitive function was negatively correlated with modified Rankin scale score. The decrease in the proportion of T lymphocytes may have predictive value for the poor prognosis of AD.